April 8, 2026
| Trial | ASpiRE |
|---|---|
| Cancer Type | Prostate Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A proof-of-mechanism and proof-of-concept clinical trial evaluating the safety, tolerability, biological and anti-tumour activity of apalutamide with dual CXCR1 and CXCR2 blockade by SX-682 for men suffering from metastatic castration-resistant prostate cancer (mCRPC) |
| Trial Open | Yes |
 |
Click Here to view trial summary |